The Clorox Company (CLX) has rallied to $92.84 after a fiscal first-quarter earnings beat, up 3.27% today and 15.8% over the past month. The balance of evidence still leans negative, with low conviction (1 of 4). The bounce sits inside a weekly downtrend, the stock is overbought, and the 200-day average at $99.58 sits overhead. Guidance of 3.5% to 4.5% organic growth helped, but much of it comes from easy comparisons.
Why it matters
Clorox reported on November 2, and the quarter cleared a low bar. Investing.com put adjusted earnings at $1.55 a share on $1.91 billion of revenue, against estimates of $1.07 and $1.88 billion. Management credited cost savings, improving market share and favorable timing benefits. The timing benefit matters because it means part of the beat is not repeatable.
The guidance carries the real argument. Seeking Alpha reports FY27 organic sales growth of 3.5% to 4.5%, including about 3.5 points from lapping the ERP transition, with underlying sales expected to dip slightly in the first half. Input cost inflation is now put at $240 million. The headline growth is mostly arithmetic, and the cost line is moving the wrong way.
The market took the news well. On earnings day the shares rose 2.16% to $89.90, and today they added another 3.27% in a session when XLP fell 1.73%. Over five days CLX is up 6.6%, while the S&P 500 (SPY) is down 2.1% and XLP is up 2.4%. The stock beat its sector by 4.2 points, so most of the move belongs to Clorox and its earnings rather than to the market or the staples group. Volume today is only in line with its 20-day average, so the rally has not drawn unusual participation.
The debate is about whether the dividend and the brands justify the price. On the constructive side, Morningstar assigns Clorox a wide moat and calls it attractive when it trades below fair value. Income writers point to a yield near 5.8%, as in Yahoo! Finance. On the cautious side, Yahoo! Finance cites a trailing payout ratio of about 103%. The Motley Fool notes organic sales fell 8% in fiscal 2026. A middle view from Seeking Alpha rates the stock a hold. It calls the payout of 83% to 88% on guided EPS of $5.70 to $6.00 high but covered, and its figure of $93.5 sits almost exactly where the stock trades now.
Valuation does not settle it. Seventeen analysts have a consensus of hold, with a mean price target of $97.76, which is 5% above the price. Targets run from $74 to $154, a spread wide enough to show the analysts disagree about whether margins recover.
What the evidence says
The long-term thesis is weakened, not broken. The stock is 27% below its 52-week high of $127.16 and below its 40-week average, which puts it in a downtrend. It is 15% above its 52-week low of $80.41. Over 200 days it trails the S&P 500 by 10.4%. This looks like a recovery attempt inside a damaged trend, not a new uptrend.
For the next 2 to 6 weeks, the balance of evidence leans negative, and conviction is low at 1 of 4. The main reason is that this is a rally inside a weekly downtrend that has reached overbought, with the 14-day RSI near 67. Pullbacks from that position are common when the larger trend is down. Relative strength points the other way: CLX leads the S&P 500 by 7.4% over 50 days and XLP by 0.3%. That counts against the negative reading, which is why conviction is low rather than moderate.
The strongest case against the negative reading is that the price has already done what buyers needed. It is above the 10-week average and the 50-day average at $87.97, it is up 15.8% in a month, and earnings beat on both lines. The 200-day average is within reach. That does not tip the balance, because the weekly trend is still down. The guidance leans on easy comparisons, and the $240 million cost headwind is still ahead. A rally this sharp also leaves little room before the first real resistance.
Levels that matter
In a downtrend, the structure holds below $98.75, where sellers have shown up on earlier rallies. The trend would end above $99.58, the 200-day average, and only on a weekly close. The two levels sit close together, and $100 just above them is a round number that adds to the overhead supply. Further up are $100.57 and $108.68.
The downside breakout level is a daily close below $92.75, a swing zone just under the current price. From there the first target is the 50-day average at $87.97, which gives 0.7 to 1 against a stop at $99.44 (the $98.75 zone plus a quarter of ATR). The second target is the 52-week low at $80.41, which gives 1.8 to 1. The math does not reach 3 to 1, and no support on the map is far enough to get there, since $80.41 is the lowest meaningful level. The $90 round number sits between the breakout and the first target.
What would change the picture
A weekly close above $99.58, the 200-day average, would be the first sign that buyers have changed the trend. The non-price fact that could produce it is evidence that underlying sales are recovering. That would mean organic growth holding up as the ERP comparison fades, with the $240 million of input cost inflation absorbed without cutting the earnings guide. That would also ease the dividend worry.
What to watch
- Earnings, February 2, 2027: the number that matters is underlying organic sales growth, set against guidance that has it dipping slightly in the first half.
- Sector: XLP moves the stock before its own news does. Today CLX rose while XLP fell, a gap that rarely lasts. Input cost headlines across household products also feed straight into the $240 million cost debate.
- Valuation: at $92.84, CLX trades 5% below the $97.76 mean target and well above the $74 low target. The consensus is hold, so the price is not far from where analysts see fair value.